Targeting GSTM3 for therapeutic potential in advanced prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Prostate cancer (PCa) is a prevalent malignancy with challenges in treating advanced stages.
• Novel molecular targets are crucial for enhancing therapeutic efficacy in advanced PCa.
• Glutathione S-transferase mu 3 (GSTM3), a detoxification enzyme, is implicated in PCa progression.

Purpose of the Study:

• To investigate the expression profile of GSTM3 in advanced PCa.
• To elucidate the functional significance of GSTM3 in PCa pathobiology.
• To evaluate GSTM3 as a potential therapeutic target for advanced PCa.

Main Methods:

• Analysis of public datasets (GEO, UALCAN) for GSTM3 expression.
• Quantitative RT-PCR validation in PCa cell lines and tumorsphere models.
• GSTM3 silencing via siRNA, followed by assessment of reactive oxygen species (ROS), mitochondrial membrane potential (mtMP), cell cycle, apoptosis, and necrosis.

Main Results:

• GSTM3 was found to be overexpressed in advanced PCa cells, with higher levels in tumorsphere models.
• GSTM3 silencing led to increased mtMP, a slight decrease in ROS, cell cycle arrest at G0/G1 phase, increased necrosis, and modest apoptosis.
• These findings demonstrate a functional role for GSTM3 in advanced PCa.

Conclusions:

• GSTM3 plays a significant role in the pathobiology of advanced prostate cancer.
• Targeting GSTM3 presents a promising novel therapeutic strategy for advanced PCa.
• Further research into GSTM3 inhibition could lead to improved clinical outcomes.